You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Details for New Drug Application (NDA): 202129


✉ Email this page to a colleague

« Back to Dashboard


NDA 202129 describes ZETONNA, which is a drug marketed by Covis and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the ZETONNA profile page.

The generic ingredient in ZETONNA is ciclesonide. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ciclesonide profile page.
Summary for 202129
Tradename:ZETONNA
Applicant:Covis
Ingredient:ciclesonide
Patents:1
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 202129
Generic Entry Date for 202129*:
Constraining patent/regulatory exclusivity:
Dosage:
AEROSOL, METERED;NASAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 202129
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129 NDA Covis Pharma US, Inc 70515-737 70515-737-60 1 CANISTER in 1 CARTON (70515-737-60) / 60 AEROSOL, METERED in 1 CANISTER

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:AEROSOL, METERED;NASALStrength0.037MG/INH
Approval Date:Jan 20, 2012TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Feb 1, 2028Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD

Expired US Patents for NDA 202129

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 ⤷  Sign Up ⤷  Sign Up
Covis ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 ⤷  Sign Up ⤷  Sign Up
Covis ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 ⤷  Sign Up ⤷  Sign Up
Covis ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 ⤷  Sign Up ⤷  Sign Up
Covis ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.